FDC International Secures UK Marketing Authorisation for Atropine 1.0% w/v Eye Drops, Solution
FDC Limited has announced that its subsidiary, FDC International Limited, has successfully received Marketing Authorisation from a leading regulatory body in the United Kingdom. The authorization covers the specialized product, Atropine 1.0% w/v Eye Drops, Solution.The Medicines and Healthcare products Regulatory Agency (MHRA), based in the UK, granted the marketing status for the eye drops manufactured by the FDC subsidiary. This development signifies a key regulatory achievement for the company's portfolio of medical products.
FDC Stock Price Movement
FDC Limited gained 1.43% in trading today, with shares settling at an indicative close of ₹358.65. The stock saw significant activity during the session, recording a total traded volume of 147,559 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.